In 2018 more people received treatment for tuberculosis than ever before, largely due to improvements in detection and diagnosis, according to the latest Global Tuberculosis Report from the WHO.
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
A novel phage-based blood assay has demonstrated its potential for identifying people at high-risk of developing tuberculosis, in addition to diagnosing established cases.
In this interview we speak to David Padley from the National Institute for Biological Standards and Control about his recent poster ‘Point-of-Care testing for HIV: specialist quality control materials are a necessity’, presented at ECCMID 2019.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
New research has identified four novel sepsis phenotypes, suggesting these could be relevant for understanding the heterogeneity of treatment effects and help to explain recent clinical trial failures.
Take a look behind the scenes of a recent Future Microbiology review, entitled: ‘Pathogen-associated acute encephalitis syndrome: therapeutics and management’, as we ask the authors about the challenges facing this field, the use of complementary and alternative medicine and what research needs to be done.
The ECDC has reported that the burden of healthcare-associated infections is substantial and variability in microbiological testing suggests these infections could be managed better, according to research presented at ECCMID.
A computer-aided model that uses routinely collected data could identify the early symptoms of sepsis, according to new research.
The accurate diagnosis of schistosomiasis, in both the mammalian and snail intermediate hosts as well as the environment, is extremely important in proper control and elimination. Despite multiple efforts over last few decades, the search for cheap, sensitive diagnostics for schistosomiasis is ongoing.
